Screening Vaccinated Women: Why Cytology Triage Matters

As HPV immunisation coverage expands globally, clinicians must adapt standard cancer prevention algorithms to changing disease epidemiology. The latest prospective observational data assess the efficacy of cervical screening vaccinated women who enter routine healthcare checks. Because vaccine uptake drastically lowers high-grade cervical lesions, traditional testing metrics undergo significant clinical shifts.

Shifting Paradigms in Cervical Screening Vaccinated Women

Widespread vaccination against high-risk human papillomavirus genotypes significantly reduces the population prevalence of cervical intraepithelial neoplasia grade 2 or worse (CIN2+). Consequently, screening tests encounter far fewer true pre-cancer cases in vaccinated populations. When disease prevalence drops, positive predictive values (PPV) naturally fall even when analytical test accuracy remains high. Therefore, healthcare providers must evaluate whether primary high-risk HPV (hrHPV) testing, cytology, or combined protocols provide optimal patient management. In routine practice, clinicians want to avoid unnecessary invasive colposcopy examinations while reliably detecting genuine pre-malignant changes. This prospective Scottish investigation offers valuable real-world evidence to guide future clinical pathways.

Key Findings from the Prospective Scottish Cohort

Researchers evaluated 10,000 co-tested residual liquid-based cytology samples from women born between 1991 and 1995. Overall, the team noted high-risk HPV positivity in 86% of borderline or mild cytology specimens. Furthermore, hrHPV was present in 27% of cytology-negative samples. Among 1,352 women attending colposcopy, clinicians confirmed 184 cases of CIN2+. Within this selective referral framework, hrHPV testing yielded a negative predictive value (NPV) of 98.9%. However, its positive predictive value for CIN2+ reached only 14.3%. In contrast, high-grade cytology demonstrated a robust PPV of 71.7% and an NPV of 89.2%. Additionally, follow-up testing across 1,007 women revealed that hrHPV clearance increased over longer intervals.

Clinical Implications for Triaging and Colposcopy

These clinical findings carry major practical lessons for gynecologists and cervical screening planners. First, a high negative predictive value confirms that a negative hrHPV test provides exceptional reassurance against underlying high-grade dysplasia. Thus, clinicians can confidently extend screening intervals for hrHPV-negative individuals. Nevertheless, the low PPV highlights a substantial risk of over-referral if doctors send every hrHPV-positive vaccinated woman directly to colposcopy. Transient HPV infections remain frequent in young adults, yet most resolve spontaneously without producing clinically meaningful neoplasia. Consequently, reflex cytology triage proves essential before making invasive colposcopy referrals. Combining primary molecular testing with cytological triage protects young women from unnecessary diagnostic biopsies and psychological distress.

Frequently Asked Questions

Q1: Why is the positive predictive value of hrHPV testing lower in vaccinated cohorts?

Because HPV vaccination dramatically reduces the baseline prevalence of cervical pre-cancers, any positive test result encounters fewer genuine CIN2+ lesions. Consequently, the positive predictive value decreases, even when the analytical specificity of the assay remains unchanged.

Q2: Can clinicians rely on a negative hrHPV test result in vaccinated women?

Yes, hrHPV testing maintains an exceptionally high negative predictive value of nearly 99%. Therefore, healthcare providers can safely reassure patients and safely extend screening intervals for hrHPV-negative women.

Q3: What role does cytology play alongside primary hrHPV testing?

Cytology functions as a vital secondary triage tool. By reserving colposcopy referrals primarily for women with abnormal cytology, clinicians prevent overtreatment and avoid unnecessary interventions for transient viral infections.

References

1. Cruickshank ME et al. Cytology and hrHPV Testing in HPV-Vaccinated Women Entering Cervical Screening: A Prospective Observational Study. BJOG. 2026 Oct 20. doi: 10.1111/1471-0528.70348. PMID: 42899485.
2. Bonde J et al. Screening outcome of HPV-vaccinated women: Data from the Danish Trial23 cohort study. PLOS ONE. 2024;19(6):e0304381.
3. World Health Organization. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention, second edition. Geneva: World Health Organization; 2021.